Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update
Connect Biopharma (NASDAQ: CNTB) reported its 2024 financial results, marking a transformative year with key leadership appointments and strategic developments. The company unveiled plans for parallel Phase 2 trials of rademikibart for acute asthma and COPD exacerbations, scheduled to begin in Q2 2025 with data expected in 2H 2026.
Financial highlights include:
- Cash position of $93.7 million as of December 31, 2024, with runway into 2027
- Revenue of $26.0 million for 2024
- Research and Development expenses decreased to $29.3 million from $53.0 million in 2023
- Net loss improved to $15.6 million ($0.28 per share) compared to $62.1 million ($1.13 per share) in 2023
The company has strengthened its U.S. presence by relocating headquarters to San Diego and transitioning to U.S.-based manufacturing and accounting operations.
Connect Biopharma (NASDAQ: CNTB) ha riportato i risultati finanziari per il 2024, segnando un anno di trasformazione con importanti nomine dirigenziali e sviluppi strategici. L'azienda ha svelato piani per prove cliniche parallele di fase 2 di rademikibart per asma acuta ed esacerbazioni di BPCO, programmate per iniziare nel secondo trimestre del 2025, con dati attesi nella seconda metà del 2026.
I punti salienti finanziari includono:
- Posizione di cassa di 93,7 milioni di dollari al 31 dicembre 2024, con liquidità fino al 2027
- Ricavi di 26,0 milioni di dollari per il 2024
- Le spese per ricerca e sviluppo sono diminuite a 29,3 milioni di dollari rispetto ai 53,0 milioni di dollari del 2023
- La perdita netta è migliorata a 15,6 milioni di dollari (0,28 dollari per azione) rispetto ai 62,1 milioni di dollari (1,13 dollari per azione) del 2023
L'azienda ha rafforzato la sua presenza negli Stati Uniti trasferendo la sede a San Diego e passando a operazioni di produzione e contabilità basate negli Stati Uniti.
Connect Biopharma (NASDAQ: CNTB) informó sus resultados financieros de 2024, marcando un año transformador con nombramientos clave en el liderazgo y desarrollos estratégicos. La compañía reveló planes para ensayos clínicos paralelos de fase 2 de rademikibart para el asma aguda y exacerbaciones de EPOC, programados para comenzar en el segundo trimestre de 2025, con datos esperados en la segunda mitad de 2026.
Los puntos destacados financieros incluyen:
- Posición de efectivo de 93,7 millones de dólares a partir del 31 de diciembre de 2024, con liquidez hasta 2027
- Ingresos de 26,0 millones de dólares para 2024
- Los gastos de investigación y desarrollo disminuyeron a 29,3 millones de dólares desde 53,0 millones de dólares en 2023
- La pérdida neta mejoró a 15,6 millones de dólares (0,28 dólares por acción) en comparación con 62,1 millones de dólares (1,13 dólares por acción) en 2023
La empresa ha fortalecido su presencia en EE. UU. al trasladar su sede a San Diego y pasar a operaciones de fabricación y contabilidad basadas en EE. UU.
Connect Biopharma (NASDAQ: CNTB)는 2024년 재무 결과를 발표하며 주요 경영진 임명 및 전략적 발전으로 변혁의 해를 맞이했습니다. 이 회사는 급성 천식 및 COPD 악화를 위한 rademikibart의 병행 2상 시험 계획을 공개했으며, 이는 2025년 2분기에 시작될 예정이며 2026년 하반기에 데이터가 예상됩니다.
재무 하이라이트는 다음과 같습니다:
- 2024년 12월 31일 기준 9,370만 달러의 현금 보유액으로 2027년까지의 운영 자금 확보
- 2024년 매출 2,600만 달러
- 연구 및 개발 비용이 2023년 5,300만 달러에서 2,930만 달러로 감소
- 순손실이 2023년 6,210만 달러(주당 1.13 달러)에서 1,560만 달러 (주당 0.28 달러)로 개선
회사는 본사를 샌디에이고로 이전하고 미국 기반의 제조 및 회계 운영으로 전환하여 미국 내 입지를 강화했습니다.
Connect Biopharma (NASDAQ: CNTB) a annoncé ses résultats financiers pour 2024, marquant une année transformative avec des nominations clés à la direction et des développements stratégiques. L'entreprise a dévoilé des plans pour des essais cliniques parallèles de phase 2 de rademikibart pour l'asthme aigu et les exacerbations de BPCO, prévus pour commencer au deuxième trimestre 2025, avec des données attendues dans la seconde moitié de 2026.
Les points forts financiers comprennent :
- Position de trésorerie de 93,7 millions de dollars au 31 décembre 2024, avec des réserves jusqu'en 2027
- Chiffre d'affaires de 26,0 millions de dollars pour 2024
- Les dépenses de recherche et développement ont diminué à 29,3 millions de dollars contre 53,0 millions de dollars en 2023
- La perte nette s'est améliorée à 15,6 millions de dollars (0,28 dollar par action) par rapport à 62,1 millions de dollars (1,13 dollar par action) en 2023
L'entreprise a renforcé sa présence aux États-Unis en déplaçant son siège à San Diego et en passant à des opérations de fabrication et de comptabilité basées aux États-Unis.
Connect Biopharma (NASDAQ: CNTB) hat seine finanziellen Ergebnisse für 2024 veröffentlicht und ein transformierendes Jahr mit wichtigen Führungswechseln und strategischen Entwicklungen markiert. Das Unternehmen hat Pläne für parallele Phase-2-Studien von rademikibart bei akuter Asthma und COPD-Verschlechterungen vorgestellt, die für das zweite Quartal 2025 geplant sind, mit Daten, die in der zweiten Hälfte von 2026 erwartet werden.
Finanzielle Highlights umfassen:
- Bargeldbestand von 93,7 Millionen Dollar zum 31. Dezember 2024, mit finanzieller Stabilität bis 2027
- Umsatz von 26,0 Millionen Dollar für 2024
- Forschung und Entwicklungskosten sanken auf 29,3 Millionen Dollar von 53,0 Millionen Dollar im Jahr 2023
- Der Nettoverlust verbesserte sich auf 15,6 Millionen Dollar (0,28 Dollar pro Aktie) im Vergleich zu 62,1 Millionen Dollar (1,13 Dollar pro Aktie) im Jahr 2023
Das Unternehmen hat seine Präsenz in den USA gestärkt, indem es seinen Hauptsitz nach San Diego verlegt und auf US-amerikanische Fertigungs- und Buchhaltungsoperationen umgestiegen ist.
- Revenue generation of $26.0M in 2024 compared to zero revenue in 2023
- Significant reduction in net loss to $15.6M from $62.1M year-over-year
- Strong cash position of $93.7M with runway into 2027
- R&D expenses decreased by $23.7M (44.7%) year-over-year
- Increased General and Administrative expenses by $3.1M due to executive departures
- Continued net loss position of $15.6M despite revenue generation
Insights
Connect Biopharma's financial results reveal significant improvement over 2023 performance. The company reported
R&D expenses declined by
The
The shift to becoming US-centric, including headquarters relocation to San Diego and transitioning to a US-based manufacturing partner, suggests strategic positioning for potential FDA approval pathways and pharmaceutical partnerships. This restructuring appears well-timed given the improvement in financial metrics and clear clinical development strategy.
Connect Biopharma's clinical development strategy for rademikibart represents a differentiated approach in respiratory disease. The company is targeting acute exacerbations in asthma and COPD - indications where no biologic therapies are currently approved. This positions rademikibart to potentially address a significant unmet need in patient populations experiencing acute respiratory episodes.
The clinical profile mentioned in the release is particularly noteworthy: rademikibart has demonstrated rapid improvement in pulmonary function in under 24 hours with sustained effects through 24 weeks. This dual rapid-onset and long-duration profile is unusual for biologics in respiratory disease and suggests potential utility across both acute and maintenance settings.
The parallel trial approach in both asthma and COPD exacerbations indicates efficient resource utilization and accelerates the development timeline. While the Q2 2025 trial initiation means catalysts are still distant, addressing both indications simultaneously creates multiple shots on goal and potential label expansion opportunities.
The strengthened management team brings substantial regulatory expertise, with collective experience in 16 FDA approvals. This enhancement to the leadership team, combined with the US-centric operational shift, demonstrates appropriate focus on navigational expertise through complex clinical and regulatory landscapes for novel biologics in respiratory disease.
Strengthened leadership team with key appointments, including Barry Quart, Pharm.D. as CEO, and David Szekeres as President, bringing deep clinical, regulatory, operational and strategic expertise
Unveiled rapid clinical development program for rademikibart initially targeting acute care in asthma and COPD; expect to initiate parallel Phase 2 trials in 2Q 2025 with data expected in 2H 2026
Strong balance sheet with cash runway into 2027 and through key clinical catalysts
SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD), today reported financial results for the year ended December 31, 2024, and provided a business update.
“2024 was a transformative year for Connect as we strengthened our leadership team, made significant progress in becoming more U.S.-centric, and unveiled a rapid clinical development strategy for rademikibart initially focused on the treatment of acute asthma and COPD exacerbations, an area where no biologic therapies have been approved. To date, rademikibart has demonstrated a differentiated clinical profile in Phase 2 clinical trials achieving rapid improvement in pulmonary function in less than 24 hours, which was sustained through 24 weeks, highlighting its potential in both acute and chronic care,” said Barry Quart, Pharm.D., CEO and Director of Connect Biopharma. “We are on track to initiate parallel Phase 2 trials of rademikibart as an adjunct to standard of care for the treatment of acute asthma and COPD exacerbations in the second quarter of 2025, with data expected in the second half of 2026. We believe rademikibart has the potential to fundamentally alter the treatment paradigm for millions of asthma and COPD patients who experience acute exacerbations every year.”
Recent Highlights
Clinical Program Highlights
- Parallel acute exacerbation trials of rademikibart as an adjunct to standard of care in asthma and COPD are on track to be initiated in the second quarter of 2025, with data expected in the second half of 2026.
Corporate Highlights
- The Company continued making progress in becoming more U.S.-centric, including by:
- assembling an experienced U.S. management team with deep expertise in drug development and regulatory execution, including having collectively received U.S. Food and Drug Administration (FDA) marketing approval for 16 therapeutic products, and with deep expertise in business development, corporate strategy, finance and operations;
- relocating its corporate headquarters to San Diego, California, a leading global hub for innovative biopharmaceutical companies;
- transferring the initial manufacturing process for rademikibart to a U.S.-based contract manufacturing organization; and
- transitioning to a U.S.-based independent registered accounting firm and voluntarily electing to become a domestic filer with the U.S. Securities and Exchange Commission (SEC), beginning with the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and on an ongoing basis with the regular filing of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
- assembling an experienced U.S. management team with deep expertise in drug development and regulatory execution, including having collectively received U.S. Food and Drug Administration (FDA) marketing approval for 16 therapeutic products, and with deep expertise in business development, corporate strategy, finance and operations;
Financial Results for the Year Ended December 31, 2024
- Cash, cash equivalents and short-term investments were
$93.7 million as of December 31, 2024. Based on its current operating plans, the Company expects that its cash, cash equivalents and short-term investments will be sufficient to fund operations into 2027. - Revenue for the year ended December 31, 2024, totaled
$26.0 million , which included revenue recognized for the upfront fee, development milestones and cost reimbursements in connection with the license agreement with Simcere Pharmaceutical Co., Ltd. There was no comparable activity for the year ended December 31, 2023. - Research and Development expense for the year ended December 31, 2024, was
$29.3 million , compared with$53.0 million for the same period in 2023, a decrease of$23.7 million . The decrease in Research and Development expense was primarily due to the completion in late 2023 of the rademikibart global Phase 2b program in patients with chronic asthma and the rademikibart China pivotal trials for patients with atopic dermatitis. - General and Administrative expense for the year ended December 31, 2024, was
$19.2 million , compared with$16.1 million for the same period in 2023, an increase of$3.1 million . The increase in General and Administrative expense was primarily due to costs associated with executive departures, including cash severance and non-cash, share-based compensation expense related to certain stock option modifications. - Net loss was
$15.6 million , or$0.28 per share, for the year ended December 31, 2024, compared with a net loss of$62.1 million , or$1.13 per share, for the same period in 2023.
About Connect Biopharma and Rademikibart
Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody. With an initial focus on acute exacerbations—an area with significant unmet need—rademikibart has the potential to also drive chronic utilization in asthma and COPD amongst the millions of asthma and COPD patients in the U.S. who experience acute exacerbations annually. In a Phase 2 trial for asthma, rademikibart demonstrated strong efficacy and safety, with clinically meaningful reductions in exacerbations and rapid, statistically significant improvements in forced expiratory volume in one second, observed within one week—and in most cases, within 24 hours via home spirometry. For more information, visit www.connectbiopharm.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended (the “Act”). Forward-looking statements are statements that are not of historical fact and include, without limitation, statements regarding future events, our cash balance, financial guidance, future financial and operating results and related expectations, business strategy and plans, prospective products (as well as their potential to achieve a differentiated, competitive, or favorable benefit or profile or trend, including on safety, tolerability, improvement, maintenance, clinical response, dosing, efficacy and/or convenience), planned or expected product approval applications or approvals, anticipated milestones, expected data readouts and enrollments, research and development plans and costs, potential future partnerships, expectations about existing partnerships, timing and likelihood of success, objectives of management for future operations, future results of anticipated product development efforts, and adequacy of existing cash and potential partnership funding to fund operations and capital expenditure requirements, as well as statements regarding industry trends. These statements are based on management’s current expectations of future events only as of the date of this press release and are inherently subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among other things: the timing and amount of actual expenses, including, without limitation, our anticipated combined U.S. GAAP R&D and G&A expenses; the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other positive results; whether we will need expanded or additional trials in order to obtain regulatory approval for our product candidates; our ability to obtain and maintain regulatory approval of our product candidates; existing regulations and regulatory developments in the U.S., the People’s Republic of China, Europe and other jurisdictions; the ability of our current cash and investments position to support planned operations; our plans and ability to obtain, maintain, protect and enforce our intellectual property rights and our proprietary technologies, including extensions of existing patent terms where available; our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials; and the degree of market acceptance of our product candidates, if approved, by physicians, patients, healthcare payors and others in the medical community.
Words such as “aim,” “anticipate,” “believe,” “could,” “expect,” “feel,” “goal,” “intend,” “may,” “optimistic,” “plan,” “potential,” “promising,” “will,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. The inclusion of forward-looking statements should not be regarded as a representation by Connect Biopharma that any of its expectations, projections or plans will be achieved. Actual results may differ materially due to the risks and uncertainties inherent in our business and other risks described in our filings with the SEC. Further information regarding these and other risks is included under the heading “Risk Factors” in our annual and periodic reports filed with the SEC. These forward-looking statements should not be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such forward-looking statements have been made are correct or exhaustive or, in the case of the assumptions, fully stated in this presentation. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You are cautioned not to place undue reliance on the scientific data presented or these forward-looking statements, which speak only as of the date of this presentation. Except as required by law, Connect Biopharma undertakes no obligation to publicly update any forward-looking statements, whether because of new information, future events or otherwise. Connect Biopharma claims the protection of the safe harbor for forward-looking statements contained in the Act for all forward-looking statements.
This press release discusses product candidates that are under clinical study, and which have not yet been approved for marketing by the FDA or by any other regulatory agency. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied. The trademarks included herein are the property of the owners thereof and are used for reference purposes only.
Connect Biopharma Holdings Limited | |||||||
Condensed Consolidated Statements of Operations | |||||||
(in thousands, except per share amounts) | |||||||
(unaudited) | |||||||
Years Ended December 31, | |||||||
2024 | 2023 | ||||||
Revenue: | |||||||
License and collaboration revenues | $ | 26,033 | $ | - | |||
Total revenue | 26,033 | - | |||||
Operating expenses: | |||||||
Research and development expense | 29,256 | 53,002 | |||||
General and administrative expense | 19,229 | 16,054 | |||||
Total operating expenses | 48,485 | 69,056 | |||||
Loss from operations | (22,452 | ) | (69,056 | ) | |||
Total other income, net | 7,047 | 7,070 | |||||
Net loss before income tax | (15,405 | ) | (61,986 | ) | |||
Income tax expense | 223 | 120 | |||||
Net loss | $ | (15,628 | ) | $ | (62,106 | ) | |
Basic and diluted net loss per ordinary share | $ | (0.28 | ) | $ | (1.13 | ) | |
Weighted-average ordinary shares outstanding, basic and diluted | 55,213 | 55,067 |
Connect Biopharma Holdings Limited | |||||
Condensed Consolidated Balance Sheet Data | |||||
(in thousands) | |||||
(unaudited) | |||||
December 31, | |||||
2024 | 2023 | ||||
Cash, cash equivalents and short-term investments | $ | 93,708 | $ | 118,303 | |
Total assets | $ | 101,284 | $ | 127,375 | |
Total shareholders' equity | $ | 92,166 | $ | 101,497 |
Investor Relations Contact:
Alex Lobo
Precision AQ
Alex.lobo@precisionaq.com
(212) 698-8802
Media Contact:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604
